In this article (Clin Cancer Res 2010;16:6150–8), which was published in the December 15, 2010 issue of Clinical Cancer Research (1), the following statement should have been included in the Grant Support section: “D.C. Talbot is supported by the NIHR Oxford Biomedical Research Centre.”

1.
Talbot
DC
,
Ranson
M
,
Davies
J
,
Lahn
M
,
Callies
S
,
André
V
, et al
Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study
.
Clin Cancer Res
2010
;
16
:
6150
8
.